Ravi Shah MBBS, MD 🇮🇳🇨🇦 @Cell4Cure

Pediatric Oncologist-BMT physician, alumnus @PSMedCollege @PGIMER @UofC @Harvard passionate about #Cancer #BMT #Immunology #CellTherapy Calgary, Alberta Joined May 2014

Tweets

763
Followers

497
Following

641
Likes

2K

Casanova Lab @casanova_lab

2 months ago

A monumental Review ! IKZF-associated inborn errors of immunity rupress.org/jhi/article/1/…

0 8 18 2K 8

Dr.Rachit Khandelwal, MD @dr_khandelwal99

2 months ago

Bone Marrow Transplantation for Sickle Cell Disease: A Study of Parents' Decisions: New England Journal of Medicine: Vol 325, No 19 1991 NEJM study found that 54% of parents of kids with sickle cell disease were willing to accept a 15% mortality risk from bone marrow…

0 1 8 302 2

Ravi Shah MBBS, MD 🇮🇳🇨🇦 @Cell4Cure

2 months ago

29% higher risk of B-cell #Acuteleukemia before 5 years of age in a child(mainly boys 41% higher risk) born through PLANNED C-SECTION!—A Swedish population‐based study. #VaginalDelivery not only prevents Allergies, Asthma or Diabetes but also #Leukemia! onlinelibrary.wiley.com/doi/10.1002/ij…

0 1 2 191 0

Goutham Sunny @medoncodoc

3 months ago

🧬✨ ATRA Goes Beyond APL! 🔬💊 All-trans retinoic acid (ATRA), the vitamin A derivative that cured APL by reactivating differentiation in leukemic blasts, is now stepping into non-APL AML 🧠🔥 🧱 In a new twist, ATRA doesn’t target blasts directly—but instead acts on the bone…

1 36 93 8K 50

Download Image

Gaurav Narula MD @DrGauravNarula

4 months ago

Out now, our bit for Low Dose ImmunoRx #LoDoNiv in relapse/refractory Ped Classic Hodgkin cHL #PHLDMG @TataMemorial Fixed #LoDoNiv 40mg + Benda -> 88%CR Will now be prospective multicenter @INPHOG study @pho_india Excellent work @Dr_Shyam_S @DHCA11 & rising star @DrAditya1996

Aditya Narayan @DrAditya1996

4 months ago

6 9 36 7K 5

Download Image

0 7 37 2K 3

Anthony DiGiorgio, DO, MHA @DrDiGiorgio

4 months ago

At many large institutions, it’s now common for nurses to have the authority to question, and sometimes override, physician decisions. This isn’t inherently a bad thing. Patient safety should always come first, and questioning orders when there's a genuine concern should be…

Anthony DiGiorgio, DO, MHA @DrDiGiorgio

4 months ago

43 27 252 80K 31

24 20 209 28K 28

Gaurav Prakash M.D. @DrGPrakash

2 years ago

and what is a high resolution typing? (5/7)

1 2 21 2K 0

Download Image

Satya Prakash Yadav @Satyayadav__

4 months ago

Checkpoint inhibitors checkmate solid tumors having genetic Mismatch repair deficiency Nonoperative Management of Mismatch Repair–Deficient Tumors nejm.org/doi/full/10.10…

0 2 8 496 1

Ravi Shah MBBS, MD 🇮🇳🇨🇦 @Cell4Cure

4 months ago

Targeted #Busulfan based #conditioning equivalent EFS/GRFS to #TBI based regimens in children with #AcuteLymphoblasticLeukemia #FORUM subgroup analysis #EBMT25. Children <2 benefited the most. Optimal #AUC (73.3-98 mg.h/L) without higher toxicity.(Same as 'Bartelink' window)

0 0 3 154 2

Download Image

Dr. Chokri Ben Lamine @abouabdrahman0

5 months ago

Intrathecal MTX Prophylaxis 💉🧠 in DLBCL: No Impact on Parenchymal CNS Relapse •Key Point: Most CNS relapses in DLBCL are parenchymal, not leptomeningeal •Implication: IT chemotherapy alone (e.g., MTX) doesn’t prevent CNS relapse •Multiple trials confirm: •RICOVER-60: 6.9%…

2 9 44 2K 24

Download Image

Ravi Shah MBBS, MD 🇮🇳🇨🇦 @Cell4Cure

5 months ago

Great work! IKAROSlow cells exhibit higher resistance to CD19, CD22-targeted therapies. Will this be applicable to #Blina also?

Pablo Domizi @DomiziPablo

5 months ago

Great work! IKAROSlow cells exhibit higher resistance to CD19, CD22-targeted therapies. Will this be applicable to #Blina also?

4 15 43 3K 6

0 0 0 131 0

Anand Raja @anandoncologist

5 months ago

link.springer.com/article/10.100… Risk adapted strategy in #Wilms #tumor works. NWTS for early staging avoiding over treatment with Adriamycin. SIOP for advanced stages avoiding tumor spill and consequent radiation. 5 year OS >90% for the entire cohort.

1 2 2 448 0

Download Image

GvHD Hub @gvhd_hub

5 months ago

📝 A new study published in @BloodJournal found that rovadicitinib treatment led to a best overall response of 86.4%, with no dose-limiting toxicities. More news: gvhdhub.com #GvHD #MedNews #MedEd

0 6 11 1K 3

Download Image

Orca Bio @OrcaBio

7 months ago

Orca Bio will present results from the pivotal Phase 3 Precision-T study of its investigational Orca-T in people with hematological malignancies at #EBMT25. The study met its primary endpoint of an improvement in survival free of moderate-to-severe cGvHD with Orca-T vs.…

0 2 4 432 0

Download Video

Jame Abraham, MD, FACP @jamecancerdoc

6 months ago

Insights into Advanced Surgical Techniques for Neuroblastoma my.clevelandclinic.org/podcasts/cance… via @ClevelandClinic @ShepardDale

0 2 9 788 1

Satya Prakash Yadav @Satyayadav__

11 months ago

#Chandrapur- From being in Naxal affected Garchiroli region to becoming home to Centre for research management and control of hemoglobinopathies #CRMCH -city has come a long way Hosting top meeting on sickle cell disease ICMR & NIH Chief guest-Dr Mohan Narla ASH president

1 1 11 856 1

Download Image

Alberto Cardoso M. Lima, PhD @AlbertoLima_HLA

a year ago

Is HLA mismatching nullified by PTCy-based GVHD prophylaxis in MMUD Transplantation? This new paper from EBMT's CTIWP, which just came out in JCO, challenges the notion that PTCy completely overcomes the deleterious impact of HLA mismatching ascopubs.org/doi/10.1200/JC…

2 18 44 4K 17

Ravi Shah MBBS, MD 🇮🇳🇨🇦 @Cell4Cure

a year ago

Another addition for treating #chronicGVHD ! @US_FDA approves axatilimab-csfr #Niktimvo. Very promising agent from pathophysiological point with low toxicity profile! #Ruxolitinib #Belumosudil #Axatilimab fda.gov/drugs/resource… #BMT